深部静脈血栓症(DVT)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0897
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Deep Vein Thrombosis (DVT) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis (DVT) – Pipeline Review, H1 2020, provides an overview of the Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline landscape.

Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema) and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease and heart failure. Treatment includes thrombolytic and anticoagulants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Deep Vein Thrombosis (DVT) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 2, 1, 2 and 3 respectively.

Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Deep Vein Thrombosis (DVT) – Overview
Deep Vein Thrombosis (DVT) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Deep Vein Thrombosis (DVT) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Deep Vein Thrombosis (DVT) – Companies Involved in Therapeutics Development
CarboMimetics
Chengdu Easton Biopharmaceuticals Co Ltd
F. Hoffmann-La Roche Ltd
Glycan Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
Marizyme Inc
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc
Deep Vein Thrombosis (DVT) – Drug Profiles
CM-20201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-3002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enoxaparin sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MB-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide to Inhibit Coagulation Factor X for Deep Vein Thrombosis and Sickle Cell Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Redesca – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zifa-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Deep Vein Thrombosis (DVT) – Dormant Projects
Deep Vein Thrombosis (DVT) – Discontinued Products
Deep Vein Thrombosis (DVT) – Product Development Milestones
Featured News & Press Releases
Nov 14, 2019: Valeo Pharma announces filing of a New Drug Submission for Low Molecular Weight Heparin in Canada
Sep 19, 2018: ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by CarboMimetics, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by Glycan Therapeutics Inc, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by Marizyme Inc, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H1 2020
Deep Vein Thrombosis (DVT) - Pipeline by Valeo Pharma Inc, H1 2020
Deep Vein Thrombosis (DVT) - Dormant Projects, H1 2020
Deep Vein Thrombosis (DVT) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Deep Vein Thrombosis (DVT) - Discontinued Products, H1 2020

【掲載企業】

CarboMimetics
Chengdu Easton Biopharmaceuticals Co Ltd
F. Hoffmann-La Roche Ltd
Glycan Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
Marizyme Inc
Tianjin Pharmaceuticals Group Co Ltd
Valeo Pharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[深部静脈血栓症(DVT)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆